The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen.
The US pharmaceutical industry may soon face major regulatory changes as six bipartisan bills designed to rein in tactics that keep drug prices high and delay generic competition close in.
Originally published in Life Sciences Intellectual Property Review - April 17, 2025.
Please see full publication below for more information.
